presentation to apsa

OBJ Limited (ACN 056 482 636)
Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007
Phone: +61 9 9443 3011 Fax: +61 9 9443 3866 Email: [email protected]
Tuesday, 6 December 2005
FOR IMMEDIATE RELEASE
PRESENTATION TO THE AUSTRALASIAN
PHARMACEUTICAL SCIENCE ASSOCIATION
ANNUAL SCIENTIFIC MEETING
==============================================
OBJ Limited (ASX:OBJ) is pleased to make available the materials to be
presented by Sarika Namjoshi BSc(Hons) of Curtin University’s Drug
Development Department to the annual scientific meeting of the Australasian
Pharmaceutical Science Association.
The invitation to present was extended jointly by the Australasian
Pharmaceutical Science Association and the Australasian Society of Clinical
and Experimental Pharmacologists and Toxicologists.
The annual meeting commenced in Melbourne on 4 December 2005 and
closes on 7 December 2005.
- END -
Background to the Announcement
OBJ Limited is a drug delivery company, specializing in electronic “drug patch”
technologies that allow drugs, vaccines, therapeutic agents and cosmetic compounds
to be delivered more effectively and more efficiently through-the-skin.
The OBJ Dermaportation system has been shown to manage and control the
transdermal delivery of a broad range of drugs and therapeutic agents ranging from
small difficult molecules such as Caffeine, through to large macro-globular proteins
drugs such as vaccines.
OBJ’s technology has been independently proven in both in-vitro and in-vivo studies
and can manage a broader range of molecular sizes, structures and valencies than
other active or passive drug delivery systems.
OBJ has been successful in
managing the through-the-skin
delivery of drugs used in the
inflammation, pain, cancer and
cosmetic fields.
OBJ’s technology is low cost, and
can be incorporated into reusable
drug patches, (as illustrated)
disposable single use drug patches
and in a range of packaging
systems for OTC and retail use.
Sustainable Benefits
Low cost and controlled through-the-skin delivery of drugs, hormones, vitamins,
vaccines, anti-bodies and anti-aging molecules has long been the desire of the
pharmaceutical industry. It would provide economic, safety and efficacy benefits to the
pharmacology, medical, veterinary and cosmetic industries. Side effects could be
reduced by localized delivery and programmed delivery rates. Needle stick injuries and
needle disposable problems could be eliminated while the reduction in the level of skill
required for application could significantly reduce total cost of many health
programmes. These clear commercial benefits may only be achievable if the skin’s
natural barrier effect can be overcome.
OBJ is the first company to create a broad spectrum through-the-skin delivery system
that is kind to the skin, completely reversible, yet can handle drugs range from the
small difficult molecules up to the largest and most complex proteins and anti-bodies.
OBJ manages an extensive IP portfolio and prosecutes patent applications throughout
the world.
Independence of Results
OBJ contracts its drug and technology testing programs to independent and respected
organisations, such as Western Australian Biomedical Research Institute, Western
Australian Institute for Medical Research, Curtin University of Technology and Murdoch
University. The high level of independence and international accreditation means that
the results attributable to OBJ’s proprietary technology can be published and presented
at major medical and scientific conferences and forums.
For more information:
Jeffrey Edwards
Phone: +61 9 944 33011 Mobile: 041 791 2211 E-mail: [email protected]